Tag: Parkinson’s disease

focused ultrasound neurotherapy

Revolution in neurotherapy? Spotlight on focused ultrasound at 2021 EAN congress

While focused ultrasound is by no means a brand-new innovation in the field of neurotherapy—having first been deployed in the 1950s, if not earlier,...
dbs long-term effectiveness

Long-term effectiveness of STN-DBS for Parkinson’s confirmed with 15-year follow-up study

New findings published in Neurology, the medical journal of the American Academy of Neurology (AAN), have confirmed the long-term effectiveness of deep brain stimulation...
exablate neuro singapore

Insightec announces approval of Exablate Neuro focused ultrasound platform in Singapore

Insightec has announced approval of its Exablate Neuro platform by the Health Sciences Authority (HSA) in Singapore. The Exablate Neuro (Exablate 4000) platform uses...
directional dbs

Benefits found in directional DBS compared to omnidirectional stimulation for Parkinson’s...

Directional deep brain stimulation (DBS) has demonstrated benefits over omnidirectional DBS for the treatment of Parkinson’s disease in the largest prospective study in this...
next-generation dbs devices

New algorithm could enable next-generation deep brain stimulation devices

By delivering small electrical pulses directly to the brain, deep brain stimulation (DBS) can ease tremors associated with Parkinson's disease or help relieve chronic...

Medtronic launches aDBS trial in Parkinson’s disease patients

Medtronic has announced the first enrolment in its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson’s...
blood test abbott

FDA approves Abbott’s iOS-compatible app for the management of chronic pain...

Abbott announces it has received approval from the US Food and Drug Administration (FDA) for the use of its Patient Controller app on compatible...

Boston Scientific announces CE mark approval of the VERCISE Neural Navigator...

Boston Scientific has announced the CE mark approval of the Vercise Neural Navigator 3 directional deep brain stimulation (DBS) programming software—the first system that...

EVER Pharma launches patient friendly subcutaneous pump for Parkinson’s disease

EVER Pharma, a company specialising in neurological diseases, announces the launch of its D-mine  Pump. This portable micro infusion device recently received European CE...

Abbott receives CE mark of MR-conditional labelling for Infinity deep brain...

Parkinson’s disease, dystonia and essential tremor patients in CE Mark countries will now benefit from upgraded functionality and new magnetic resonance (MR) conditional labelling...

Boston Scientific launches Vercise primary cell and Vercise Gevia deep brain...

The launch of the Vercise primary cell (PC) and Vercise Gevia deep brain stimulation (DBS) systems, featuring the Vercise Cartesia Directional Lead (Boston Scientific)...

FDA approval of Exablate Neuro for the treatment of tremor-dominant Parkinson’s...

InSightec has announced that The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) has approved an expansion...

Deep brain stimulation associated with a decreased risk of fall in...

Chronic subthalamic deep brain stimulation (DBS) is associated with a decreased risk for recurrent falls and delays the onset of psychosis in patients with...

Vercise deep brain stimulation system gains FDA approval

The US Food and Drug Administration (FDA) has approved the Vercise deep brain stimulation (DBS) system (Boston Scientific). DBS is used to treat the symptoms...

FDA approves pivotal study of Exablate Neuro for treatment of Parkinson’s...

INSIGHTEC has received approval from the US Food and Drug Administration (FDA) to initiate a pivotal study of the Exablate Neuro for treating dyskinesia...

Aleva Neurotherapeutics raises US$13 million in latest financing round

Aleva Neurotherapeutics has raised US$13 million in a Series D financing round. The round was led by Forrestal Capital, a fund with specific experience...

XADAGO (safinamide) now available in the USA for Parkinson’s disease patients

XADAGO (safinamide) is now available as an add-on therapy for US patients with Parkinson’s disease currently taking levodopa/carbidopa and experiencing “off” episodes. It is not...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Transcranial stimulation and/or physical therapy improves walking speed in Parkinson’s disease

Non-invasive brain stimulation and physical therapy—alone or in combination—improve some measures of walking ability in patients with Parkinson’s disease, concludes a clinical trial in...

Parkinson’s disease patients first to be treated with Leksell Vantage Stereotactic...

The Leksell Vantage Stereotactic system (Elekta) is now in clinical use at three European centres. The first surgeries were performed on a patient with...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

CE mark for Vercise Gevia deep brain stimulation system

CE mark has been granted for the Vercise Gevia deep brain stimulation (DBS) system (Boston Scientific), a rechargeable, magnetic resonance (MR) conditional device indicated...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

SureTune3 deep brain stimulation software receives Health Canada licence

Medtronic has received a Health Canada licence for SureTune3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology are designed...

First patient enrolled in APPRISE clinical study for optimisation of Parkinson’s...

  Global Kinetics Corporation (GKC) and the Parkinson’s Foundation have announced that the first of over 400 patients has been enrolled in the GKC APPRISE...

Blood test may help differentiate Parkinson’s from atypical Parkinsonism disorders

A blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson’s disease or...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Spinal cord stimulation leads to “significant improvement” in gait in Parkinson’s...

A recent study explores the safety and efficacy of spinal cord stimulation on gait disturbance in advanced Parkinson’s disease. The investigators found that spinal...

Infinity deep brain stimulation system approved in the USA

St Jude Medical has announced the United States Food and Drug Administration approval and first implant of the Infinity deep brain stimulation (DBS) system...

Study finds deep brain stimulation a cost-effective treatment method for Parkinson’s...

It has been established that deep brain stimulation is clinically superior to medical therapy for treating advanced Parkinson’s disease. Jan B Pietzsch (Department of...